Previous 10 | Next 10 |
2023-11-13 21:25:23 ET Harrow, Inc. (HROW) Q3 2023 Earnings Conference Call November 13, 2023 16:45 ET Corporate Participants Jamie Webb - Director-Communications & Investor Relations Mark Baum - Chief Executive Officer Andrew Boll - Chief Financial Officer ...
2023-11-13 18:01:34 ET Gainers: Theseus Pharmaceuticals ( THRX ) +35% . GENFIT ( GNFT ) +15% . Lifeway Foods ( LWAY ) +9% . Digital World Acquisition ( DWACW ) +8% . Digital World Acquisition ( DWAC ) +5% . Lose...
2023-11-13 16:08:09 ET More on Harrow Health Implications Of Harrow's Short-Term Guidance Harrow Health's 5-Year Guidance Seeking Alpha’s Quant Rating on Harrow Health Historical earnings data for Harrow Health Financial information for Harrow ...
Third Quarter 2023 and Recent Selected Highlights: Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase of 2% over $33.5 million in the sequential quarter. GAAP net loss of $(4.4 million). Adjusted EBITDA of $9.2 million, ...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Harrow Inc Com (HROW) is expected to report $0.03 for Q3 2023
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2023, on Monday, November 13, 2023, after the market close. The Company will also post its third quarter Letter to Stockholder...
Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications (NDAs) for the following products: FLAREX® (fluorometholone acetate ophthalmic suspension) 0.1%, a corticosteroid indicated fo...
2023-10-18 09:34:25 ET Summary Harrow has provided long-term revenue guidance of $1B in 2027. If they deliver on this, the shares are likely to head north of $100. Perhaps a lot north. In order to deliver as promised, Harrow needs to succeed in its bold move into branded pharmaceu...
2023-09-29 08:22:20 ET More on Harrow Health Harrow Health's 5-Year Guidance Harrow Health, Inc. 2023 Q2 - Results - Earnings Call Presentation Harrow Health, Inc. (HROW) Q2 2023 Earnings Call Transcript Harrow prices $60 million stock offering; sees Q2 reven...
News, Short Squeeze, Breakout and More Instantly...
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2024, on Wednesday, August...
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual Meeting, taking place in Stockholm, Sweden, from July 17-20, 2024. The ASRS Annual Meeting brings tog...
Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, ...